Table 3.

A suggested approach to management of relapsed ALL.

Risk Group (%*)
Type of Relapse
EFS
Possible Treatment
High (25%)   Early bone marrow or combined
 
5-15%
 
  • Intensify early chemotherapy

  • New agents as available

  • Sibling or unrelated donor transplant

  • Modification of transplant approach

 
  Early CNS with adverse factors   20-25%   

 
? Early testis
 

 

 
Medium (65%)   Bone marrow relapse 2-4 yr.
 
40-60%
 
  • Sibling transplant

  • Use minimal residual disease to stratify

  • Randomize minimal residual disease-negative to transplant vs. chemotherapy

 

 
Combined relapse
 
40-60%
 

 
Low (10%)   Very late bone marrow relapse
 
? 60-70%
 
  • Intensified chemotherapy

  • Local irradiation as appropriate

 

 
Late extramedullary relapse
 
60-80%
 

 
Risk Group (%*)
Type of Relapse
EFS
Possible Treatment
High (25%)   Early bone marrow or combined
 
5-15%
 
  • Intensify early chemotherapy

  • New agents as available

  • Sibling or unrelated donor transplant

  • Modification of transplant approach

 
  Early CNS with adverse factors   20-25%   

 
? Early testis
 

 

 
Medium (65%)   Bone marrow relapse 2-4 yr.
 
40-60%
 
  • Sibling transplant

  • Use minimal residual disease to stratify

  • Randomize minimal residual disease-negative to transplant vs. chemotherapy

 

 
Combined relapse
 
40-60%
 

 
Low (10%)   Very late bone marrow relapse
 
? 60-70%
 
  • Intensified chemotherapy

  • Local irradiation as appropriate

 

 
Late extramedullary relapse
 
60-80%
 

 
*

Estimated proportion of all relapses

Close Modal

or Create an Account

Close Modal
Close Modal